1. Comparison of glaucomatous progression between untreated patients with normal-tension   glaucoma and patients with therapeutically reduced intra-ocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol 1998; 126(4): 487-497 
  2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol 2006; 90(3): 262-267 
  3. Casson J R, Chidlow G, Ebneter A, Wood J PM, Crowston J, Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clinical and Experimental Ophthalmology 2012; 40: 350-357 
  4.  Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114: 1965-72
  5. Jonas JB, XU L. Optic disc morphology in eyes after nonarteritic anterior isquemic optic neuropathy. Invest Ophthalmol Vis Sci. 1993; 34: 2260-2265
  6. Jonas JB, Hayreh SS. Optic disk morphology in experimental central retinal artery occlusion in rhesus monkeys. Am J Ophthalmol. 1999; 127: 523-530
  7. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy. Surv of Ophthal 2007; 52: 162-173
  8. Flammer J, Mozaffarieh M. Is there more to glaucoma treatment than lowering IOP? Surv of Ophthal 2007; 52S2: 174-179
  9. Morgan WH, Yu DY, Alder VA, et al. The correlation between cerebrospinal fluid pressure and the retrolaminar tissue pressure. Invest Ophthalmol Vis Sci, 1998; 39:1419-1428
  10. Jonas JB. Role of cerebrospinal fluid pressure in the pathogenesis of glaucoma. Acta Ophthalmol 2011 Sep;89(6):505-14. doi: 10.1111/j.1755-3768.2010.01915.x. Epub 2010 Apr 28
  11. Morgan WH, Yu DY, Cooper RL, Alder VA, Cringle SJ, Constable IJ. The influence of cerebrospinal fluid pressure on the lamina cribosa tissue pressure gradient. Invest Ophthalmol Vis Sci. 1995; 36: 1163-1172
  12. Morgan WH, Chauhan BC, Yu DY, Cringle SJ, Alder VA, House PH. Optic disc movement with variations in intraocular and cerebrospinal fluid pressure. Invest Ophthalmol Vis Sci 2002; 43: 3236-42
  13. Morgan WH, Yu DY, Balaratnasingam C. The role of cerebrospinal fluid pressure in glaucoma pathophysiology: the dark side of the optic disc. J Glaucoma 2008; 17: 408-413.
  14. Anderson DR, Hendrickson A. Effect of intraocular pressure on rapid axoplasmatic transport in monkey optic nerve. Invest Ophthalmol 1974; 13:771-783
  15. Minckler DS, Tso MOM, Zimmermann LE. A light microscopic autoradiographic study of axonal transport in the optic nerve head during ocular hipotony, increased intraocular pressure, and papilledema. Am J Ophthalmol 1976; 82: 741-757
  16. Ren R, Jonas JB, Tian G, Zhen Y, Ma K, Li S, Wang H, Li B, Zhang X, Wang N. Cerebrospinal fluid pressure in glaucoma. A prospective study. Ophthalmology 2010; 117:259-66
  17. Ren R, Zhang X, Wang N, Li B, Tian G, Jonas JB. Cerebrospinal fluid pressure in ocular hypertension. Acta Ophthalmol 2011; 89: 142-8
  18. Ren R, Wang NL, Zhang X, Cui T, Jonas JB. Trans-lamina cribosa pressure difference correlated with neuroretinal rim area in glaucoma. Graefes Arch Clin Exp Ophthalmol. Epub 2011 Apr 1
  19. Chang EE, Goldberg JL. Glaucoma 2.0: Neuroprotection, Neurogegeneration, Neuroenhancement. Ophthalmology 2012; 119: 979-986
  20. Chen SD, Wang L, Zhang XI. Neuroprotection in glaucoma: present and future – Review article. Chinese Medical Journal 2013; 126(8): 1567-77
  21. Brett H. Mueller II, Dorota L. Stankowska and Raghu R. Krishnamoorthy (2011). Neuroprotection in Glaucoma, Glaucoma - Basic and Clinical Concepts, Dr Shimon Rumelt (Ed.), ISBN: 978-953-307-591-4, InTech, DOI: 10.5772/18465. Acessível em:
  22. Chidlow G, Melena J, Osborne NN. Betaxolol, a β(1)-adrenoreceptor antagonist, reduces Na+ influx into cortical synaptosomes by direct enteraction with Na+ channels: comparison with other β-adrenoreceptor antagonists. Br J Pharmacol 2000; 130(4), 759-766
  23. Melena, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Opthalmol 2001; 239(7), 522-530
  24. Wood JP, DeSantis L, Chao HM, Osborne NN. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp Eye Res 2001; 72(1), 79-86
  25. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-Pressure Glaucoma Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005; 112 (3), 376-385
  26. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from de Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011 Apr; 151(4): 671-81 doi: 10.1016/j.ajo.2010.09.026. Epub 2011 Jan 22
  27. Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther 1999; 15(3): 189-197
  28. Kniep EM, Roehelecke C, Ozkucur N et al. Inhibition of apoptosis and reduction of intracellular pH descrease in retinal neural cell cultures by a blocker of carbonic anhydrase. Invest Ophthalmol Vis Sci 2006; 47(3): 1185-1192
  29. Seki M, Tanaka T, Matsuda H et al. Topically administered timolol and dorzolamide reduce intra-ocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model Br J Ophthalmol 2005; 89(4): 504-507
  30. Schuettauf F, Quinto K, Naskar R, Zurakowski D. Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res 2002; 42(20): 2333-2337
  31. Pascale A, et al. Protecting the retinal neurons from glaucoma: Lowering ocular pressure is not enough. Pharmacol Res (2012), doi:10.1016/j.phrs.2012.03.002
  32. Virno M, Pecori-Giraldi J, Liguori A, De Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (Perimetric study with a 10-year follow-up). Acta Ophthalmologica Scandinávica 2000:  56-57
  33. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5’-diphosphocholine (citicoline): a study of 8 years of follow-up. Documenta Ophthalmologica 2005;110: 91-102
  34. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5’diphosfocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999; 106: 1126-34
  35. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Revista de Neurologia April 2011; 52: Supplement 2
  36. Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates an glaucomatous visual field progression correlate? Uer J Ophthalmol. 2011 Jul-Aug; 21 (4): 410-4.
  37. Caprioli J, Coleman AL. Intraocular pressure fluctuation: A risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology 2008; 138: 684-685
  38. Crowston JG, Lerner SF, He M, Singh K, Healey P. Risk Factors. In Weinreb RN, Garway-Heath DF, Leung C, Crowston JG, Medeiros FA (EDs.), Progression of Glaucoma. The 8th Consensus Report of the World Glaucoma Association. Kugler Publications, Amsterdam, The Netherlands 2011, p 110
  39. Kóthy P, Tóth M, Holló G. Influence of selective laser trabeculoplasty on 24-hour diurnal intra-ocular pressure fluctuation in primary open-angle glaucoma: a pilot study. Ophthalmic Surg Lasers Imaging. 2010 May-Jun; 41(3): 342-7
  40. Prasad N, Murthy S, Dagianis JJ, Latina MA. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. J Glaucoma. 2009 Feb; 18(2): 157-60
  41. Medeiros FA, Pinheiro A, Moura FC, Leal BC, Sesanna R Jr. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther. 2002 Dec; 18(6):489-98
2ª Edição - Outubro 2013